Developing new drugs to block influenza virus entry
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
This study is working on new medicines that can help stop the flu virus from getting into your cells, which could be really helpful for people, especially during flu season or pandemics when current treatments aren't working well.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Chicago Biosolutions, INC. NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10833557 on NIH RePORTER |
What this research studies
This research focuses on creating new small molecule inhibitors that can effectively block the entry of influenza A viruses into cells. Current treatments for influenza are limited, especially with the emergence of resistant strains, making this research crucial for developing alternative therapies. The approach involves synthesizing and testing various compounds to identify those that can inhibit the virus effectively. Patients may benefit from these new treatments, especially during flu seasons or pandemics when existing options are inadequate.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at high risk for influenza complications, including those with weakened immune systems or those living in areas with high rates of influenza infection.
Not a fit: Patients who are not at risk for influenza or those who have already been vaccinated and are not experiencing symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new antiviral medications that are effective against resistant strains of influenza A, improving treatment options for patients.
How similar studies have performed: Other research has shown promise in developing antiviral therapies targeting different mechanisms of influenza, indicating that this approach could lead to significant advancements.
Where this research is happening
Chicago, United States
- Chicago Biosolutions, INC. — Chicago, United States (Active)
Researchers
- Principal investigator: Rong, Lijun — Chicago Biosolutions, INC.
- Study coordinator: Rong, Lijun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.